Author

G. Gimenez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:gene regulatory network inference· 4 Organism:human· 4 Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

J. Antony· 2 shared A. Ahn· 1 shared A. Bigas· 1 shared A. Braithwaite· 1 shared A. Chatterjee· 1 shared A. J. George· 1 shared A. Montoto· 1 shared A. Villanueva· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Antony

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

IKK1 kinase coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy

L. Espinosa, I. Pecharroman Ruiz, L. Sole, D. Alvarez-Villanueva, T. Lobo, J. Alonso, j. Bertran, E. Sabido, E. Borras, V. Garcia-Hernandez, M. garrido, J. Seoane, A. Bigas, A. Villanueva, M. Martinez-Iniesta, , R. salazar

This study identifies IKK1's role in coordinating BRD4 and JAK/STAT signaling to resist DNA damage-based therapy in colorectal cancer.

bioRxiv · Jun 13, 2023 · PreprintCancer Biology

Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumor necrosis factor signaling pathways

A. Ahn, E. J. Rodger, G. Gimenez, P. A. Stockwell, M. Parry, P. Hersey, A. Chatterjee, M. Eccles

bioRxiv · Jun 15, 2021Cancer Biology

Cohesin mutations are synthetic lethal with stimulation of WNT signaling

C. V. Chin, J. Antony, S. Ketharnathan, G. Gimenez, K. M. Parsons, J. He, A. J. George, A. Braithwaite, P. Guilford, R. D. Hannan, J. A. Horsfield

The paper identifies GSK3 inhibitors as synthetic lethal with cohesin mutations, revealing Wnt pathway activation as a therapeutic target in cohesin mutant cancers.

bioRxiv · Jul 23, 2020Cancer Biology

BET inhibition prevents aberrant RUNX1 and ERG transcription in STAG2 mutant leukaemia cells.

J. Antony, G. Gimenez, T. Taylor, U. Khatoon, R. C. Day, I. M. Morison, J. Horsfield

This study shows that BET inhibition reduces aberrant RUNX1 and ERG transcription in STAG2 mutant leukemia cells by blocking enhancer-driven gene expression during differentiation.

bioRxiv · Sep 10, 2019Cancer Biology